Literature DB >> 24638980

Cancer stem-like cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells.

Tsunaki Yamashina1, Muhammad Baghdadi1, Akihiro Yoneda1, Ichiro Kinoshita1, Shinya Suzu1, Hirotoshi Dosaka-Akita1, Masahisa Jinushi2.   

Abstract

Resistance to anticancer therapeutics greatly affects the phenotypic and functional properties of tumor cells, but how chemoresistance contributes to the tumorigenic activities of cancer stem-like cells remains unclear. In this study, we found that a characteristic of cancer stem-like cells from chemoresistant tumors (CSC-R) is the ability to produce a variety of proinflammatory cytokines and to generate M2-like immunoregulatory myeloid cells from CD14(+) monocytes. Furthermore, we identified the IFN-regulated transcription factor IRF5 as a CSC-R-specific factor critical for promoting M-CSF production and generating tumorigenic myeloid cells. Importantly, myeloid cells primed with IRF5(+) CSC-R facilitate the tumorigenic and stem cell activities of bulk tumors. Importantly, the activation of IRF5/M-CSF pathways in tumor cells were correlated with the number of tumor-associated CSF1 receptor(+) M2 macrophages in patients with non-small lung cancer. Collectively, our findings show how chemoresistance affects the properties of CSCs in their niche microenvironments. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24638980     DOI: 10.1158/0008-5472.CAN-13-2169

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

Review 2.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

Review 3.  Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies.

Authors:  C Raggi; H S Mousa; M Correnti; A Sica; P Invernizzi
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

Review 4.  New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

Authors:  Armel Hervé Nwabo Kamdje; Paul Faustin Seke Etet; Lorella Vecchio; Richard Simo Tagne; Jeremie Mbo Amvene; Jean-Marc Muller; Mauro Krampera; Kiven Erique Lukong
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

Review 5.  Cancer Stem Cells: The Architects of the Tumor Ecosystem.

Authors:  Briana C Prager; Qi Xie; Shideng Bao; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2019-01-03       Impact factor: 24.633

6.  Small cell lung cancer: Recruitment of macrophages by circulating tumor cells.

Authors:  Gerhard Hamilton; Barbara Rath; Lukas Klameth; Maximilan J Hochmair
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

Review 7.  Immune targeting of cancer stem cells in gastrointestinal oncology.

Authors:  Robert J Canter; Steven K Grossenbacher; Erik Ames; William J Murphy
Journal:  J Gastrointest Oncol       Date:  2016-04

8.  Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer.

Authors:  Krishan Kumar; Christina R Chow; Kazumi Ebine; Ahmet D Arslan; Benjamin Kwok; David J Bentrem; Frank D Eckerdt; Leonidas C Platanias; Hidayatullah G Munshi
Journal:  Mol Cancer Res       Date:  2015-11-25       Impact factor: 5.852

Review 9.  Interplay between inflammatory tumor microenvironment and cancer stem cells.

Authors:  Shijian Zhang; Xi Yang; Lei Wang; Chenping Zhang
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

Review 10.  Cancer stem cell-immune cell crosstalk in tumour progression.

Authors:  Defne Bayik; Justin D Lathia
Journal:  Nat Rev Cancer       Date:  2021-06-08       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.